Results for tag: "Circulating Tumor Cells Prognostic Technologies"

The Circulating Tumor Cells (CTCs) prognostic technology market is a domain within the broader field of biomarkers, concerned with the isolation and analysis of CTCs in cancer patients. CTCs are cells that have shed from a primary tumor into the vasculature or lymphatic system and circulate through the bloodstream. The detection and characterization of these cells play a vital role in cancer prognosis, as their presence is often associated with metastatic disease and can provide critical information on tumor progression, treatment efficacy, and potential relapse. Technologies in this market segment aim to enhance the accuracy, sensitivity, and specificity of CTC capture and analysis, integrating various methodologies such as immunomagnetic separation, microfluidics, and advanced imaging techniques. Several companies operate within the CTC prognostic technology market, offering innovative platforms and assays to facilitate the capture and analysis of circulating tumor cells. Notable players include Menarini Silicon Biosystems, which provides the CELLSEARCH® system, the first FDA-cleared test for CTC detection in patients with metastatic breast, colorectal, or prostate cancer. Another company, Epic Sciences, has developed a no-cell-left-behind platform that creates high-definition images of cells, aiding in the comprehensive analysis of CTCs. Furthermore, companies like Biocept, Inc. offer assays and services for CTC and biomarker analysis in cancer, and ANGLE plc focuses on the Parsortix cell separation system, which isolates rare cells from blood Show Less Read more